FTC’s Pharmaceutical Antitrust Suit Over Opioid License Agreement Between Endo and Impax Dismissed Because Patent Act Permits Exclusive Licenses READ MORE
Timing is Everything: Subsequent Invalidity Ruling Does Not Excuse Violation of an ITC Exclusion Order READ MORE
Federal Circuit Denies Rehearing in Biogen v. Mylan: Dissent Raises Four Written Description “Points of Error” That En Banc Court Should Have Corrected READ MORE
The Federal Circuit in Alarm.com Incorporated v. Hirshfeld: Parties CAN Seek Review of USPTO Director’s Decision to Vacate Ex Parte Reexamination READ MORE
Haug Partners Wins “Battle of the Experts” In Claim Construction Decision on Takeda’s Vyvanse® READ MORE
California, Rest In Peace: Pharmaceutical Companies, Keep Your Settlement Discussions Out of California READ MORE
NHK-Fintiv Frustration: Status of the Current Challenges and the Uncertain Fate of the PTAB’s Discretionary Denial of IPRs READ MORE
